News & Updates

RNA interference with zilebesiran shows therapeutic potential in mild-to-moderate hypertension

Zilebesiran, an investigational RNA interference therapeutic agent that targets hepatic angiotensinogen synthesis, appears to have a promising blood pressure (BP)-lowering effect in adults with mild-to-moderate hypertension, according to the phase II KARDIA-1 trial.

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

Veterans of Iraq and Afghanistan who sustained moderate/severe and penetrating traumatic brain injury (TBI) are at increased risk of developing brain cancer, as shown in a study.

5-year survival more likely in mBCC patients with nodal vs distant metastasis

Among patients with metastatic basal cell carcinoma (mBCC), those with nodal disease appear to have a higher chance of remission, while individuals with distant metastasis tend to have persistent disease and subsequently die from it, a recent study reveals. However, the survival rates at 5 years surpass 50 percent even for those with stage IV disease.

Patch test a boon to dupilumab-treated patients

A prospective, multicentre study has demonstrated the efficacy of patch tests (PTs) for patients who are being treated with dupilumab.

Hypertension, Telmisartan and Clinical Practice Guidelines in the Philippines: Upholding International Standards in Local Practice

Hypertension in the Philippine Setting

While the Expanded National Nutrition Survey (NNS) conducted by the Food and Nutrition Research Institute (FNRI) using cross-sectional questionnaire and a single-visit BP measurement has shown a significant decline in the prevalence of hypertension from 23.9% in 2013 to 19.2% in 2018, hypertension continues to impose a significant healthcare and socio-economic burden in the Philippines.¹

While it is acknowledged to be the most important modifiable risk factor for disability adjusted life-years worldwide, hypertension awareness in the Philippines is at 67.8% with only 75% of those who are aware receive treatment. Of those under treatment, only 27% have it under control.¹

COVID-19 shots offer durable protection in IBD population

Adults with inflammatory bowel disease (IBD) benefit from COVID-19 vaccination, with its protective effect lasting up to 52 weeks postvaccination even among vulnerable populations such as corticosteroid users and older individuals, according to a study.